Black FridayUp to 80% OFF
Novo-Nordisk A/SNovo-Nordisk A/SNovo-Nordisk A/S

Novo-Nordisk A/S

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Trade ideas

NVO Turns Bearish! Clean Breakdown Below Weighted MA💼🐻 NVO Bearish Playbook — Weighted MA Breakdown | Thief Layered Sell Setup 🚨 Asset: NVO – Novo Nordisk (NYSE) 📝 Style: Swing / Day Trade Profit Playbook 📉 Bias: Bearish momentum confirmed after Weighted Moving Average (WMA) breakout 📉 Trade Plan — Clean Bearish Setup Activated The bearish structure is confirmed as price breaks under the Weighted Moving Average, signaling that upside power is weakening and sellers are gaining full control. Momentum, structure, and trend all align for a controlled downside thief-style opportunity 😈📉 🎯 Thief Layered Entry Strategy (Professional Version) Thief strategy = multiple staggered limit orders to catch premium fill levels. Here’s the setup ⬇️ 🔥 Sell Limit Layers: 49.00 48.00 47.00 46.00 (You can extend or increase layers based on your own risk preferences. Thief OG’s know the drill 😎🕶️) 👉 Any price level is allowed — this is a flexible layering system designed for optimal fills when liquidity sweeps occur. 🛑 Stop Loss — Thief Escape Hatch SL @ 52.00 ⚠️ Dear Ladies & Gentlemen (Thief OG’s): This SL is not a recommendation — trade your own plan, adjust based on your personal risk. You make the money; you take the money at your own risk. Stay sharp 🦊📛 💰 Target Zone — Police Barricade Support Zone Police barricade = strong support area + oversold pocket + liquidity trap potential 🚧🎯 📌 Final Target: 36.00 ⚠️ Again, dear Thief OG’s: TP is your own choice — this is not a fixed recommendation. Manage profits based on your strategy and risk appetite. 📊 Key Notes for Traders Bearish momentum confirmed through WMA breakdown Layered entries help reduce overall cost and increase probability of catching liquidity spikes Target aligns with strong historical support + oversold metrics SL placed above structural invalidation & liquidity pocket 🌍 Related Markets to Watch (Correlation & Behavior) These pairs/stocks often react with similar flows due to healthcare sector momentum and large-cap institutional rebalancing: 🩺 Healthcare Stocks to Watch: NYSE:LLY (Eli Lilly) → Strong correlation in pharma trend rotations NYSE:PFE (Pfizer) → Tracks sentiment in healthcare risk cycles NYSE:MRK (Merck) → Often mirrors sector weakness or defensive flows 📈 Broader Market Influence: AMEX:SPY → Large-cap direction impacts NVO’s liquidity flow AMEX:XLV (Healthcare ETF) → Best sector barometer for confirmation NASDAQ:QQQ → Tech risk-on cycles can reduce defensive pharma demand 🧩 Key Correlation Points: Defensive sectors weaken → Pharma tends to retrace deeper Strength in USD → Pressure on foreign-listed healthcare stocks Broad risk-off → Market-wide liquidity tightening supports bearish setups ✨ “If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!” 🔒 Disclaimer: This is a thief-style trading strategy just for fun. Trade at your own risk.
NYSE:NVOShort
by The-Thief
1
NVO USThe decline in Novo Nordisk shares is not the result of a single factor, but rather the result of a complex set of fundamental issues: weakening financial performance, loss of competitive advantage in key products, and increased strategic risks. While negative data on Eli Lilly's weight loss pill in August 2025 triggered a temporary optimistic rebound in NVO shares, it failed to reverse the overall downward trend caused by the company's deeper structural problems. Now, in order: Operating and Financial Results Sales and operating profit growth forecasts for 2025 have been lowered twice; Q3 2025 results below expectations Operating margin fell to 41.7% from 44.7% (YoY), gross margin decreased to 81.0% from 84.6% Free cash flow declined 11% due to a sharp increase in capital expenditures Competitive pressure: Superiority of Eli Lilly products. Zepbound (Eli Lilly) demonstrates greater effectiveness in weight loss (20.2% vs. 13.7% for Wegovy); Mounjaro overtook Ozempic in diabetes sales. NVO's CagriSema failed to meet expectations in clinical trials. Companies such as Viking Therapeutics, Altimmune, Roche, and Amgen are developing promising anti-obesity drugs, threatening the Novo Nordisk-Eli Lilly duopoly. The company recently agreed to set a "maximum fair price" for Medicare under the Inflation Reduction Act. As a result of the deal, the price of Wegovy for certain patient categories is also expected to drop to $149 per month, compared to the current starting price of $1,349. Such a sharp price reduction will directly impact revenue and profits. Novo Nordisk's share of the US GLP-1 market fell to 43%, while Eli Lilly's grew to 57%. To protect profitability, Maziar's new CEO, Mike Dusdar, initiated stringent cost-cutting measures, including a hiring freeze, layoffs, and a 23.8% reduction in R&D spending. While this may support cash flow in the short term, this strategy raises concerns about long-term innovation. Eight R&D projects were terminated, potentially slowing the market launch of promising next-generation drugs such as CagriSema and oral semaglutide. NVO shares attempted a reversal around $60, but then this figure became a mirror level, and investors sold en masse from this price, which is certainly concerning. The chart shows volumes around $60. Be that as it may, the price is now below $50, and we can see the market trying to catch a low, trying to cling to any level. We're expecting a lower price.
NYSE:NVOShort
by A3MInvestments
NVO long-term TAThere's a good chance that Novo Nordisk will shine again! Technically speaking the volumes and the indicators have not turned bullish yet, but despite of the long downtrend the indicators have been improving for quite some time, weekly accumulation is rising steadily, which signals positive divergence, the current area of $40-45 is good for the support and potential new uptrend in the process. Can it dive even lower? Sure it can but that will push the divergence even higher. In short, keep an eye on NVO.
NYSE:NVO
by MoxGo_Analytics
$NVO Faces Market Pressure Follow by Alzheime Clinical TrialShares of Novo Nordisk (NYSE: NVO) found themselves among the session's most significant decliners on Monday, pressured by discouraging news from the pharmaceutical giant's pipeline. The company announced that its highly anticipated clinical trial, which investigated the use of its GLP-1 semaglutide drug in treating Alzheimer's disease, failed to meet its primary objective. The study was designed to determine if the medication could slow the progression of symptoms associated with the neurodegenerative condition; however, the results indicated no statistically significant benefit for patients. In response to the news, Novo Nordisk's CEO, Mike Doustdar, sought to manage expectations by characterizing the trial as a longshot from its inception. He emphasized that the primary focus for the company's GLP-1 portfolio remains firmly on metabolic diseases like diabetes and obesity. Despite this framing, the market's reaction was decisively negative. The Alzheimer's space is notoriously challenging, with a long history of failed treatments, and investors had held out hope that Novo's proven platform could finally deliver a breakthrough. The disappointment stems not only from a missed commercial opportunity but also from the dashed hopes for a new therapeutic avenue for the millions affected by Alzheimer's. From a technical analysis perspective, the negative catalyst has reinforced a bearish chart pattern for $NVO. The stock is currently tracing a descending pattern, indicating sustained selling pressure. For investors and traders monitoring these levels, a critical support zone is established near the $30.00 mark. A decisive breach of this support level could trigger further downside, with the next significant area of concern, often termed the "danger zone," located around $20.00. Conversely, should the stock successfully hold the $30.00 support and subsequently reverse its downward trajectory, breaking out above the pattern's resistance, a substantial upward move could be in sight. In such a bullish reversal scenario, the primary upside target would be projected near the $60.00 level, representing a significant recovery and a test of prior highs.
NYSE:NVOLong
by KalaGhazi
NVO: Harmonic Pattern Signals Potential ReversalNVO: Harmonic Pattern Signals Potential Reversal Novo Nordisk (NVO) has completed a Bullish Harmonic Pattern, suggesting that a potential reversal phase may already be underway. If the pattern holds, we could see a short consolidation before a potential rally toward the first target near 53.50, followed by the second target around 58.50. However, we should keep an eye on price stability near the current lows. A break below could invalidate the pattern setup. Key Targets: 🎯 53.50 🎯 58.50 You may find more details in the chart! Thank you and Good Luck! ❤️PS: Please support with a like or comment if you find this analysis useful for your trading day❤️
NYSE:NVOLong
by KlejdiCuni
9
Novo bottom is in novo has had a 200% gain without any major correction. we have a 60% retracement that is sitting on a confluence of support.we have bottomed on the macd 15 day and have a positive reversal forming on the smaller time . i feel we have bottomed out and am taking a position accordingly. we also are seeing huge volume and testing support to make a floor and reversal. i am personally backing up the dump truck on this one. as we also see in the news a lot of bullish talk about the medical industry even thou i dont trade on news sociological target 100. and top of channel with a potential 100x gains
NYSE:NVOLong
by Mrbigman
$NVO Short Setup | EMA Wall Stops Bulls, Downside Active🎯 NVO Bearish Breakdown: 200 EMA Rejection Setup 🐻 📊 Asset Overview Novo Nordisk (NVO) - NYSE Type: Swing/Day Trade Opportunity Bias: Bearish Reversal Confirmed ⚠️ 🔍 Technical Analysis The bulls just got rejected harder than a bad pickup line at the 200 EMA! 📉 We're seeing strong bearish momentum building up with heavy downside pressure taking control. The market structure screams reversal, and bears are flexing their dominance. Key Technical Factors: 🚫 200 Exponential Moving Average acting as dynamic resistance 📉 Bearish momentum accelerating with high selling pressure 🔄 Clear market structure reversal pattern forming 🐻 Bears in full control of price action 💰 Trade Setup - "The Thief Strategy" 🎯 Entry Strategy Layering Method - Multiple limit orders for optimal positioning: Layer 1: $53.00 Layer 2: $52.00 Layer 3: $51.00 Feel free to add more layers based on your risk appetite and account size! 🛑 Stop Loss Thief SL: $56.00 ⚠️ Risk Disclaimer: This is MY stop loss level. You're the captain of your own ship - adjust based on your risk tolerance and trading plan. Trade at your own risk! 🎯 Target Zone Primary Target: $44.00 📍 Why $44? Strong support confluence + oversold conditions + potential bull trap zone. Smart money takes profits where the crowd panics! ⚠️ Profit Taking Note: This is MY target. You make your money, you take your money. Don't be greedy - secure those gains when YOUR plan says so! 🔗 Related Pairs to Watch Keep your eyes on these correlated assets for confirmation: 📈 Pharma/Healthcare Sector: NYSE:LLY (Eli Lilly) - Direct competitor in diabetes/obesity space NASDAQ:SNY (Sanofi) - European pharma correlation AMEX:XLV (Healthcare ETF) - Sector-wide momentum gauge 💵 Currency Impact: TVC:DXY (US Dollar Index) - Strong dollar = pressure on international stocks $EUR/USD - Danish Krone correlation (Denmark-based company) 💊 Related Healthcare Plays: NYSE:JNJ (Johnson & Johnson) - Large-cap healthcare sentiment NYSE:PFE (Pfizer) - Big pharma correlation Watch for divergences or confirmations across these pairs to validate the bearish thesis! 📝 Key Points Summary ✅ 200 EMA rejection = institutional selling zone ✅ Bearish market structure confirmed ✅ Multiple entry layers = better average price ✅ Strong support target at $44 = ideal exit zone ✅ Risk management is KING 👑 ⚡ The Thief's Edge This "layering strategy" lets you build positions gradually while managing risk like a pro. Instead of going all-in at one price, you spread your entries to capture the best average. It's not about timing the perfect entry - it's about stacking the odds in your favor! 🎲 🎭 The Thief Strategy: A playful nickname for layered limit order entries. Trade responsibly and within your means. ✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community! #NVO #NovoNordisk #BearishSetup #SwingTrading #DayTrading #TechnicalAnalysis #StockMarket #NYSE #ThiefStrategy #LayeringStrategy #PharmaStocks #200EMA #BearishReversal #TradingIdeas #PriceAction #RiskManagement #Healthcare #BiopharmaTrade
NYSE:NVOShort
by The-Thief
7
Novo Nordisk selloff an opportunity if markets slumpMarkets are stretched. Tech and AI have run hot. If sentiment breaks, investors will pivot fast. Novo Nordisk offers safety, scale, and cashflow. But this isn’t a flawless story. Novo’s stock has pulled back. Some of that is market-driven. But part of it is real. Growth expectations were stretched. Wegovy demand is strong, but competition from Eli Lilly is rising. The obesity drug market is now a battleground. Margins will face pressure. There’s also a deeper issue. Novo’s growth beyond GLP‑1 is uncertain. The pipeline is solid, not spectacular. Expansion into areas like NASH and cardiovascular disease will take time. Execution risk is high. Regulators are watching pricing and access. Political pressure could mount, especially in the US. Still, Novo remains a global leader in metabolic health. The company is profitable, disciplined, and forward-looking. Oral versions of its drugs could open up new markets. And its ability to scale production is unmatched. If we see a broad selloff in growth and tech, money will move. Healthcare offers earnings stability. Within healthcare, Novo trades at a more reasonable multiple than peers, with less patent cliff risk. This isn’t a moonshot. It’s a quality business, temporarily mispriced. Risks exist, but they’re known and manageable. Growth won’t be as smooth as before, but it’s still there. And when the market rotates, Novo will be in demand. For traders, this is about timing. For investors, it’s about conviction. Either way, it deserves a place on the radar. The forecasts provided herein are intended for informational purposes only and should not be construed as guarantees of future performance. This is an example only to enhance a consumer's understanding of the strategy being described above and is not to be taken as Blueberry Markets providing personal advice.
NYSE:NVOLong
by Blueberry
$NVO Last opportunity!🌱 Novo Nordisk: A Healthy Pullback in a Long-Term Growth Story After years of remarkable growth, Novo Nordisk (NYSE: NVO) has seen its stock cool off — sliding from over 💲130 to around 💲49. At first glance, that might look alarming, but the reality is far more balanced. What we’re seeing is an organic correction after a period of exceptional hype, not a collapse of fundamentals. 💉 From Breakthrough Buzz to Market Reset The rally through 2022–2023 was powered by massive excitement over Ozempic and Wegovy, Novo Nordisk’s revolutionary GLP-1 drugs transforming diabetes and weight-loss treatment. As the world caught on, valuations skyrocketed — but eventually, markets needed to breathe. Profit-taking, competition from Eli Lilly’s Mounjaro, and normalization of expectations triggered the current pullback. 📈 The Bigger Picture Zooming out tells a very different story — over the decades, Novo Nordisk’s stock has gained over 30,000% 🚀, riding steady innovation and strong global demand. Even now, the long-term uptrend remains intact, with the stock retesting support around $45–$50, a level that previously served as a major base. 💡 A Discounted Opportunity? For long-term investors, this phase could be an opportunity to accumulate a quality company at a discount. Novo Nordisk continues to lead in metabolic treatments, maintain strong margins, and expand production — all pillars of sustainable growth. While no one can predict the short-term, history suggests this pullback may simply be the market’s way of resetting before the next phase of growth. 🧠 Educational Takeaway 🔁 Strong fundamentals can lead to temporary overvaluation during hype cycles. 📉 Pullbacks are natural and healthy in long-term uptrends. 💎 Quality companies often reward patience when bought during corrections. In short: Novo Nordisk’s story isn’t broken — it’s evolving. This dip may be less of a warning sign and more of a lesson in long-term investing discipline. 🌍📊
NYSE:NVOLong
by alexei_erchov
14
NVO-Hold or cut lossIt has been quite a crappy month for this stonk. But if this pull back(if it is turn out to be a pull back) can hold firm support at fib 0.78 level at around $48. Then we can still expect a reversal to the upside to be play out. But is we loose this or previous low then we will probably see another lower low. With current undervaluation of this stock, with bullish weekly bullish divergent still intact, I believe we are more like to make a reversal to the upside from here
NYSE:NVO
by JustBuyAndPrayToTheChart
Time to go Long NVO?NVO has had a tough year. It's down 53% ytd. I accumulated 100 shares at $50 in August and stupidly held the bag despite the price hitting my target of 60. The price is back down around $50, and looking like a good time to buy. If you look down at the RSI the last 2 times it sunk to oversold, it triggered runs of 10-20pts. Personally, I think the stories of increased competition are overblown. This is the largest company in Europe and still a leader. The share price needs help from some US gov't policy, but it's definitely in its accumulation zone again. Moreover, it looks like it could finally break the downward trendline started back in December. Share prices dopped to $50 once again today on the news that it's bidding on Metsera. And on the news, I bought another 100 shares. This trade is active.
NYSE:NVOLong
by brendanvanson